HOTH Stock Summary and Trading Ideas (Hoth Therapeutics | NASDAQ:HOTH)

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Hoth Therapeutics trades on the NASDAQ stock market under the symbol HOTH.

As of April 3, 2025, HOTH stock price declined to $0.93 with 309,533 million shares trading.

HOTH has a beta of -1.66, meaning it tends to be less sensitive to market movements. HOTH has a correlation of 0.04 to the broad based SPY ETF.

HOTH has a market cap of $12.27 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, HOTH traded as high as $40.74 and as low as $.58.

The top ETF exchange traded funds that HOTH belongs to (by Net Assets): VXF.

HOTH has underperformed the market in the last year with a price return of -31.9% while the SPY ETF gained +4.8%. However, in the short term, HOTH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +21.1% vs -7.9% return in SPY. But in the last 2 weeks, HOTH shares have been beat by the market, returning -10.3% compared to an SPY return of -5.1%.

HOTH support price is $.92 and resistance is $1.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOTH shares will trade within this expected range on the day.